» Articles » PMID: 7873579

Complementary Roles of Mutations at Positions 69 and 242 in a Class A Beta-lactamase

Overview
Specialties Biochemistry
Biophysics
Date 1995 Feb 22
PMID 7873579
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Analysis of the three-dimensional structure of class A beta-lactamases suggests that deformation of the substrate binding site can be produced by changes in the hydrophobicity of residue 69 behind the beta-sheet and by outward movement of the B3 beta-strand by introduction of a non-glycine residue at position 242 on the B4 beta-strand. By site-directed mutagenesis Met69-IleGly242-Cys, a double mutant, of the OHIO-1 beta-lactamase, was constructed. The minimum inhibitory concentrations (MICs) of the double mutant compared with the wild type and each single mutant revealed an increased susceptibility to beta-lactams. Met69-IleGly242Cys hydrolyzed cephaloridine (Km = 213 microM) but had Km > 500 microM for other beta-lactams tested including cefotaxime, and demonstrated a higher apparent Ki for inhibitors (clavulanate Ki = 500 microM sulbactam = 434 microM, and tazobactam = 70 microM). In a competition experiment with cephaloridine, the apparent Ki values for penicillin and cefotaxime remained low, 21 microM and 0.7 microM, respectively. Since Ile is twice as hydrophobic as Met, the Met69-Ile mutation may result in partial collapse of the oxyanion hole. This would also increase the distance between Arg-244 and the carboxyl of clavulanic acid. The Gly242-Cys mutation opens the lower portion of the active site to bulky R groups of cephalosporins. Although these two mutations result in a catalytically impaired enzyme, they can be used to model the complementary role of two distinct residues, neither of which interacts directly with beta-lactam substrates or inhibitors.

Citing Articles

Exposing a β-Lactamase "Twist": the Mechanistic Basis for the High Level of Ceftazidime Resistance in the C69F Variant of the Burkholderia pseudomallei PenI β-Lactamase.

Papp-Wallace K, Becka S, Taracila M, Winkler M, Gatta J, Rholl D Antimicrob Agents Chemother. 2015; 60(2):777-88.

PMID: 26596949 PMC: 4750712. DOI: 10.1128/AAC.02073-15.


TEM-109 (CMT-5), a natural complex mutant of TEM-1 beta-lactamase combining the amino acid substitutions of TEM-6 and TEM-33 (IRT-5).

Robin F, Delmas J, Chanal C, Sirot D, Sirot J, Bonnet R Antimicrob Agents Chemother. 2005; 49(11):4443-7.

PMID: 16251281 PMC: 1280126. DOI: 10.1128/AAC.49.11.4443-4447.2005.


SHV-49, a novel inhibitor-resistant beta-lactamase in a clinical isolate of Klebsiella pneumoniae.

Dubois V, Poirel L, Arpin C, Coulange L, Bebear C, Nordmann P Antimicrob Agents Chemother. 2004; 48(11):4466-9.

PMID: 15504885 PMC: 525401. DOI: 10.1128/AAC.48.11.4466-4469.2004.


Kinetic analysis of an inhibitor-resistant variant of the OHIO-1 beta-lactamase, an SHV-family class A enzyme.

Lin S, Thomas M, Shlaes D, Rudin S, Knox J, Anderson V Biochem J. 1998; 333 ( Pt 2):395-400.

PMID: 9735103 PMC: 1219605. DOI: 10.1042/bj3330395.


Selection and characterization of beta-lactam-beta-lactamase inactivator-resistant mutants following PCR mutagenesis of the TEM-1 beta-lactamase gene.

Vakulenko S, Geryk B, Kotra L, Mobashery S, Lerner S Antimicrob Agents Chemother. 1998; 42(7):1542-8.

PMID: 9660980 PMC: 105642. DOI: 10.1128/AAC.42.7.1542.